Under terms of the agreement announced June 21, Arrowhead will conduct all activities through preclinical stages of development of the drug. Horizon will receive a worldwide exclusive license to the drug and will be wholly responsible for clinical development and commercialization.
“We believe Horizon’s expertise in the clinical development and commercialization of therapies for gout makes them an ideal partner,” Christopher Anzalone, Arrowhead’s chief executive, said in the announcement. “This collaboration with Horizon also represents further expansion of our rapidly growing pipeline of investigational RNAi therapeutics.”